Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Tempest Therapeutics

< Previous 1 2 Next >
Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Announces $4.6 Million Registered Direct Offering of Common Stock
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Reports First Quarter 2025 Financial Results and Provides Business Update
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Reports Year End 2024 Financial Results and Provides Business Update
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Extends Limited Duration Stockholder Rights Plan
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control Arm
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.